Health Trials

Advanced or Metastatic Merkel Cell Carcinoma

2

Review clinical trials related to Advanced or Metastatic Merkel Cell Carcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 118 participants will be randomized to receive either IFx-Hu2.0 or placebo via intralesional injection in a single lesion, followed by pembrolizumab.

Participants needed: 118
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: TuHURA Biosciences, Inc.Updated: Apr 17, 2026Locations: 18
Eligibility criteria

At least 18 years of age. [+8]

Uncontrolled intercurrent illness including, but not limited to, ongoing or acti... [+6]

Read more
Status: Recruiting

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion followed by pembrolizumab.

Participants needed: 9
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: TuHURA Biosciences, Inc.Updated: Oct 15, 2025Locations: 2
Eligibility criteria

At least 18 years of age. [+7]

Uncontrolled intercurrent illness including, but not limited to, ongoing or acti... [+6]

Read more